Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2831127 | 0.89 | NAMPT (0.59) | NAMPTGRM5GRM1PDK4BTK | |
| SCHEMBL27602036 | 0.87 | NAMPT (0.49) | NAMPTMAPTHDAC1MAPK1GRM5 | |
| SCHEMBL1781247 | 0.84 | LNPEP (0.48) | NAMPTLNPEPMEN1KMT2APRMT1 | |
| SCHEMBL25201639 | 0.84 | NAMPT (0.50) | NAMPTLNPEPMAPTMEN1KMT2A | |
| SCHEMBL4878961 | 0.81 | NAMPT (0.44) | NAMPTMAPTHDAC1MAPK1GRM5 | |
| SCHEMBL21590409 | 0.80 | LNPEP (0.46) | NAMPTLNPEPPRMT1GRM5GRM1 | |
| SCHEMBL5473100 | 0.80 | NAMPT (0.65) | NAMPTMAPTGRM5GRM1PDK4 | |
| SCHEMBL12479633 | 0.79 | NAMPT (0.52) | NAMPTLNPEPGRM5GRM1PDK4 | |
| SCHEMBL22563072 | 0.79 | GRM5 (0.52) | HDAC2LNPEPMAPTMEN1KMT2A | |
| SCHEMBL12801757 | 0.79 | LNPEP (0.48) | NAMPTLNPEPMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735429-B2 | Benzamide compounds useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| EP-1954690-B1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-05-15 | — | — | EP | disclosed |
| US-20120225907-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-06 | — | — | US | disclosed |
| US-8207202-B2 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2012-06-26 | — | — | US | disclosed |
| US-8207202-B2 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2012-06-26 | — | — | US | disclosed |
| US-20080269294-A1 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269294-A1 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2007045844-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225907-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC5 | HDAC2 4/4885NAMPT 423/4885LNPEP 2839/4885 |
| US-20080269294-A1 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | HDAC1, HDAC5, HDAC2 | HDAC2 3/4885NAMPT 431/4885LNPEP 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.